Ohio Medicaid spending on GLP-1 drugs
How much did Ohio Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?
Pharmacies were reimbursed at least $407.0 million for GLP-1 drugs paid through Ohio Medicaid in 2025, across at least 425,347 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 115 rows of 357, so these figures are floors.
Pharmacies were reimbursed at least $88.5 million for GLP-1 drugs paid through Ohio Medicaid in 2026 (quarter 1 only, as posted so far), across at least 90,654 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 26 rows of 96, so these figures are floors.
By year and ingredient
| 2020 | at least $11,271,758 | No data | at least $42,952,433 | at least $68,865,438 | at least $3,577,716 | at least $65,773 | at least $829,692 | at least $213,219 | at least $127,776,029 |
| 2021 | at least $14,935,945 | No data | at least $40,061,165 | at least $118,048,243 | at least $1,717,865 | at least $11,946 | at least $678,725 | $198,672 | at least $175,652,561 |
| 2022 | at least $28,557,597 | at least $5,305,319 | at least $37,559,088 | at least $185,165,979 | at least $1,238,662 | Suppressed | at least $555,896 | $168,345 | at least $258,550,885 |
| 2023 | at least $48,147,487 | at least $33,005,182 | at least $35,073,470 | at least $248,513,074 | at least $1,242,013 | No data | at least $480,799 | at least $168,519 | at least $366,630,545 |
| 2024 | at least $37,695,889 | at least $27,612,957 | at least $17,082,821 | at least $262,113,555 | at least $1,410,815 | No data | at least $287,531 | at least $50,007 | at least $346,253,575 |
| 2025 | at least $28,399,648 | at least $29,543,280 | at least $6,194,208 | at least $342,355,815 | at least $297,241 | No data | $153,454 | at least $11,188 | at least $406,954,834 |
| 2026 (Q1) | at least $7,713,865 | at least $9,981,924 | at least $1,268,003 | at least $69,472,365 | at least $26,466 | No data | at least $19,529 | Suppressed | at least $88,482,152 |
By product, 2025
| Ozempic | at least $16,995,782 | at least 17,542 | 4 of 28 |
| Rybelsus | at least $1,188,879 | at least 1,197 | 9 of 25 |
| Wegovy | at least $10,214,988 | at least 7,780 | 10 of 41 |
| Mounjaro | at least $26,368,761 | at least 25,193 | 18 of 65 |
| Zepbound | at least $3,174,520 | at least 2,992 | 22 of 40 |
| Liraglutide (generic name listing) | at least $1,982,784 | at least 4,292 | 14 of 47 |
| Saxenda | at least $72,944 | at least 62 | 4 of 7 |
| Victoza | $4,138,480 | 6,622 | 0 of 16 |
| Trulicity | at least $342,355,815 | at least 359,093 | 20 of 62 |
| Bydureon | at least $20,903 | at least 26 | 2 of 3 |
| Byetta | at least $209,568 | at least 255 | 6 of 9 |
| Exenatide (generic name listing) | at least $66,770 | at least 89 | 3 of 6 |
| Soliqua | $153,454 | 192 | 0 of 4 |
| Xultophy | at least $11,188 | at least 12 | 3 of 4 |
By quarter, 2025
| Q1 2025 | at least $94,550,584 | at least 99,582 | 29 of 83 |
| Q2 2025 | at least $102,322,010 | at least 106,980 | 30 of 90 |
| Q3 2025 | at least $104,821,056 | at least 109,436 | 27 of 89 |
| Q4 2025 | at least $105,261,184 | at least 109,349 | 29 of 95 |
By quarter, 2026 (posted so far)
| Q1 2026 | at least $88,482,152 | at least 90,654 | 26 of 96 |
The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:
“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”
Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”
CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.
Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.
Sources
- CMS Medicaid State Drug Utilization Data (Medicaid.gov)
- State Drug Utilization Data 2020 (data.medicaid.gov)
- State Drug Utilization Data 2021 (data.medicaid.gov)
- State Drug Utilization Data 2022 (data.medicaid.gov)
- State Drug Utilization Data 2023 (data.medicaid.gov)
- State Drug Utilization Data 2024 (data.medicaid.gov)
- State Drug Utilization Data 2025 (data.medicaid.gov)
- State Drug Utilization Data 2026 (data.medicaid.gov)
Records last pulled Nov 15, 2026. Every entry links to the original public record.